Maria Acelia Marrero
Research Subjects
Research Interests
Maria Acelia Marrero has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Aurelie Mauras
Center for Atomic Energy, Paris, France, France
1 shared publication - Carlos Alberto Guzman
Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany
1 shared publication - Cécile Herate
Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Viral Diseases (IMVA-HB/IDMIT), Paris, France
1 shared publication - Eduardo Pentón-Arias
Center for Genetic Engineering and Biotechnology, Havana, Cuba, Cuba
1 shared publication - Gerardo Guillen
Research Department, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba
1 shared publication - Guillermo Fernandez
Center for Genetic Engineering and Biotechnology, Havana, Cuba, Cuba
1 shared publication
Latest Publications
- Open Access
- 19 August 2024
- Published by MDPI AG in Preprints.org
Therapeutic Vaccination in Chronic Hepatitis B: A Systematic Assessment by the HeberNasvac Therapeutic Vaccine Team
The immune system is central in controlling acute hepatitis B infection and in patients resolving chronic hepatitis B (CHB). Given that 221 million (75%) of CHB patients reside in low- and middle-income countries, developing a vaccine with therapeutic properties represents a rational and cost-effective approach more than a romantic endeavor. This review systematically analyses the critical variables related to the safety, efficacy, and effectiveness of CHB treatments. HeberNasvac's experience is revisited to address the challenges and potentialities of therapeutic vaccines, as well as the current roadblocks in research and development, registration, and large-scale implementation.
- 19 August 2024
- Published by MDPI AG in Preprints.org
Open AccessTherapeutic Vaccination in Chronic Hepatitis B: A Systematic Assessment by the HeberNasvac Therapeutic Vaccine Team
The immune system is central in controlling acute hepatitis B infection and in patients resolving chronic hepatitis B (CHB). Given that 221 million (75%) of CHB patients reside in low- and middle-income countries, developing a vaccine with therapeutic properties represents a rational and cost-effective approach more than a romantic endeavor. This review systematically analyses the critical variables related to the safety, efficacy, and effectiveness of CHB treatments. HeberNasvac's experience is revisited to address the challenges and potentialities of therapeutic vaccines, as well as the current roadblocks in research and development, registration, and large-scale implementation.